Akèy › Metiyè › Bioengineers and Biomedical Engineers › Indianapolis, IN
Bioengineers and Biomedical Engineers nan Indianapolis, IN: Salè H-1B
33 aplikasyon kondisyon travay pou okipasyon sa a ak yon sit travay nan Indianapolis, IN. Salè baz medyàn ofri $106,434; mwatye mitan $89,850–$118,548.
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $99,316 |
| Nivo II (kalifye) | $91,700 |
| Nivo III (eksperyans) | $108,720 |
| Nivo IV (plen kompetans) | $141,540 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| Eli Lilly and Company | 14 | $109,360 |
| Roche Diagnostics Corporation | 5 | $106,434 |
| The RND Group LLC | 2 | $115,000 |
| Indiana University Indianapolis | 2 | $85,870 |
| Elanco US Inc. | 2 | $118,548 |
| PAXAFE, Inc. | 1 | $81,931 |
| Adjutant Solutions Group | 1 | $65,853 |
| NICO Corporation | 1 | $88,000 |
| Micronutrients USA, LLC | 1 | $95,000 |
| Novartis Services Inc. | 1 | $104,374 |
| Advanced Accelerator Applications USA, Inc. | 1 | $104,374 |
| IU Health Care Associates | 1 | — |
| Roche Diabetes Care, Inc. | 1 | $91,700 |
Tit travay
- Verification Lead2
- Automation Scientist2
- Sr. Principal Engineer - IAPI2
- Sr. Associate - IDM QC2
- Assistant Professor2
- Lead Engineer2
- Advisor, Oligonucleotide Characterization1
- Chief Technology Officer1
- Principal Scientist1
- Technical Project Manager1
- Associate FES1
- Technical Project Manager and Systems Engineer1
- Product Development Engineer1
- Process Engineer1
- Sr. Engineer - Process - IAPI1
Pwonse H-1B nan Indianapolis, IN →
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).